Watch the source · TBPN

TBPN on Moderna’s Cancer Therapy Leak and Stock Drop

Name: TBPN on Moderna’s Cancer Therapy Leak and Stock Drop
Uploaded: 2026-10-23T20:04:47Z
Duration: 1 h 52 min 57 s
Channel: TBPN
Description: The show said leaked phase-three data disappointed investors despite a successful trial.

1:52:571 min for the key points · 99% time saved

All key points

Read the points below. Tap a timestamp to play it in the video above.

01
TBPN described the “Moderna drama” as leaked clinical data from Moderna’s cancer therapy amid speculation that the company had “cured cancer,” while calling that description overly broad. Timestamp: 01: 38.
Play this point here · 1:38
02
TBPN described the treatment as a patient-specific mRNA vaccine based on tumor mutations and used alongside Merck’s Keytruda. Timestamp: 03: 43.
Play this point here · 3:43
03
The show contrasted an earlier 49% relative-risk reduction with a later phase-three result of 42%. Timestamp: 06: 11.
Play this point here · 6:11
04
Moderna’s announcement that its 1,137-patient phase-three trial succeeded did not include the underlying figure, and detailed data leaked two days before the scheduled presentation. Timestamp: 05: 22.
Play this point here · 5:21
05
After the leak, Moderna fell 26% intraday and closed down 18%; TBPN said the trial succeeded but was less spectacular than investors expected. Timestamp: 05: 57.
Play this point here · 5:56
06
TBPN said the treatment appeared to become effective only after about six months and highlighted Shane “Togi” Stofer’s pre-leak options trade, characterizing the timing as largely lucky. Timestamps: 06: 33 and 11: 28.
Play this point here · 6:33

AI summary

TBPN described the “Moderna drama” as leaked clinical data from Moderna’s cancer therapy after speculation that the company had “cured cancer.” The hosts said that phrase was overly broad, while describing the results as promising. The show said Moderna had announced that its 1,137-patient phase-three trial succeeded without giving the underlying number. Detailed results then leaked two days before the scheduled presentation. TBPN contrasted an earlier 49% relative-risk reduction with a later phase-three result of 42%.

After screenshots of the embargoed data circulated on X, the show said Moderna fell 26% intraday and closed down 18%. The hosts described a patient-specific mRNA vaccine based on tumor mutations and used with Merck’s Keytruda. They also said the treatment appeared to start working after about six months, making it less useful for fast-growing cancers. TBPN also discussed Shane “Togi” Stofer’s options trade before the leak, presenting the timing as a lucky outcome rather than a reliable strategy.

TBPN on Moderna’s Cancer Therapy Leak and Stock Drop

All key points

TBPN described the “Moderna drama” as leaked clinical data from Moderna’s cancer therapy amid speculation that the company had “cured cancer,” while calling that description overly broad. Timestamp: 01: 38.

TBPN described the treatment as a patient-specific mRNA vaccine based on tumor mutations and used alongside Merck’s Keytruda. Timestamp: 03: 43.

The show contrasted an earlier 49% relative-risk reduction with a later phase-three result of 42%. Timestamp: 06: 11.

Moderna’s announcement that its 1,137-patient phase-three trial succeeded did not include the underlying figure, and detailed data leaked two days before the scheduled presentation. Timestamp: 05: 22.

After the leak, Moderna fell 26% intraday and closed down 18%; TBPN said the trial succeeded but was less spectacular than investors expected. Timestamp: 05: 57.

TBPN said the treatment appeared to become effective only after about six months and highlighted Shane “Togi” Stofer’s pre-leak options trade, characterizing the timing as largely lucky. Timestamps: 06: 33 and 11: 28.

AI summary

You may also like

Ben Shapiro frames Sophia Franklin’s abortion distress as moral and spiritual

What Copeland and Griffith said about Billy Evans on Hard Fork

Why Zelenskyy Says He Stayed in Kyiv During Russia’s Invasion

Tony Smith’s view of the UK border system’s main failures

Shapiro’s View of Ramaswamy’s Acton Ad

The News Agents: Trump envies Zelensky and admires Putin’s power